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Radiotherapy plays an important role in managing highly radiosensitive, indolent non-
Hodgkin lymphomas, such as follicular lymphoma andmarginal zone lymphoma. Although
the standard of care for localized indolent non-Hodgkin lymphomas remains 24 Gy,
de-escalation to very-low-dose radiotherapy (VLDRT) of 4 Gy further reduces toxicities and
duration of treatment. Use of VLDRT outside palliative indications remains controversial;
however, we hypothesize that it may be sufficient for most lesions. We present the largest
single-institution VLDRT experience of adult patients with follicular lymphoma ormarginal
zone lymphoma treated between 2005 and 2018 (299 lesions; 250 patients) using modern
principles including positron emission tomography staging and involved site radiotherapy.
Outcomes include best clinical or radiographic response between 1.5 and 6 months after
VLDRT and cumulative incidence of local progression (LP) with death as the only competing
risk. After VLDRT, the overall response rate was 90% for all treated sites, with 68%
achieving complete response (CR). With a median follow-up of 2.4 years, the 2-year
cumulative incidence of LP was 25% for the entire cohort and 9% after first-line treatment
with VLDRT for potentially curable, localized disease. Lesion size .6 cm was associated
with lower odds of attaining a CR and greater risk of LP. There was no suggestion of inferior
outcomes for potentially curable lesions. Given the clinical versatility of VLDRT, we propose
to implement a novel, incremental, adaptive involved site radiotherapy strategy in which
patients will be treated initially with VLDRT, reserving full-dose treatment for those who
are unable to attain a CR.
Introduction
Radiotherapy (RT) is an integral component of the management of indolent non-Hodgkin lymphomas
(iNHLs) such as follicular lymphoma (FL) and marginal zone lymphoma (MZL). The foundation of treating
iNHL with RT was established before noninvasive staging or effective systemic therapies, which
necessitated treatment to broad fields using high doses.1 Although disease management has evolved, RT
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Key Points
 Two doses of VLDRT
at 2 Gy are associated
with an impressive
overall response rate
of 90% across diverse
indolent B-cell
lymphomas.




similar to those treated
with 4 Gy as part of a
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remains a highly effective tool for treatment and is supported by
guidelines for curative and palliative indications.2,3
Given the long natural history of iNHL, reducing treatment-associated
toxicities is paramount. For RT, this has been accomplished through
better RT delivery techniques, volume reductions from extended field
to involved field radiotherapy (IFRT) to involved site radiotherapy
(ISRT),4,5 and through dose de-escalation. The first major systematic
dose reduction occurred after the British National Lymphoma
Investigation study,6 which randomly assigned 361 indolent sites
(mostly in FL or MZL) to receive 24 Gy or 40 to 45 Gy. Patients
treated with 24Gy had no differences in response or local control and
significantly less dermatitis, which established a new standard.
Modern positron emission tomography (PET)–guided RT for localized
FL is associated with excellent control of local and overall disease.7
Furthermore, most patients with localized disease who relapse after
definitive RT can achieve a successful outcomewith salvage therapy.8
For many, particularly those who receive palliative care, further dose
reduction is reasonable. It has been established that iNHL can be
remarkably radiosensitive; for example, patients with advanced-stage
disease can achieve sustained responses to just 1.5 to 2.5 Gy total
body irradiation.9-13 The now common very-low-dose radiotherapy
(VLDRT) regimen of 2 Gy 3 2 fractions (total dose of 4 Gy) matured
from these observations and early clinical experience.14 The first
series of 48 patients demonstrated an excellent overall response rate
(ORR) of 81% and a complete response (CR) rate of 57%, with
median freedom from local progression (LP) over 4 years.15 Numer-
ous subsequent reports16-22 confirmed efficacy with CR rates of 36%
to 84% across heterogeneous contexts. The benefits of VLDRT to
patients are clear; fewer RT sessions reduce clinical and financial
toxicities.23
Encouraging data motivated the phase 3 Follicular Radiotherapy Trial
(FoRT), which randomly assigned 614 FL or MZL sites from 548
patients to receive 24 Gy or 4 Gy.24,25 Initial inclusion criteria limited
the study to only those patients who required palliation, but the criteria
were expanded to include curative intent. The primary outcome was
time to LP using a noninferiority design.With amedian follow-up of 6.2
years, VLDRT was inferior to 24 Gy (hazard ratio [HR] of LP, 3.5; P,
.0001) in both the curative and palliative settings. However, there was
no significant difference in overall survival (OS) and similar proportions
of patients who subsequently required systemic therapy.25 The
authors advocate that 24 Gy remains standard of care when durable
local control is paramount, and 4 Gy should be limited to palliative
treatment.
Broader use of VLDRT thus remains controversial, particularly for
curative intent. Critics of an expanded role cite clearly inferior local
progression-free survival. Proponents acknowledge that while 24 Gy
produces more durable responses, 70% of sites treated with VLDRT
remain controlled at 5 years.25 FL and MZL are indolent diseases of
the elderly, and no differences in OS suggest that salvage treatment
can be used successfully for patients who experience treatment failure
after VLDRT.26
At Memorial Sloan Kettering Cancer Center, we support the latter
interpretation, which hypothesizes that 4 Gy is sufficient for most
lesions and that additional RT may constitute overtreatment. We
increasingly integrate VLDRT into an adaptive RT program, in which
potential patients are offered VLDRT with short-interval PET/com-
puted tomography (CT) scanning after robust informed discussion.
Early evaluation informs whether 4 Gy is sufficient or whether
additional ISRT should be offered. In our experience, given the
indolence of the disease, few curable patients progress in the short
interval after 4 Gy and previous reassessment, which supports the
suitability of an incremental strategy. Because there are no firmly
established clinicodemographic predictors of improved response to
VLDRT, we offer this program broadly, including to select curable
patients with localized iNHL.
Following this strategy, we have analyzed what is (to the best of our
knowledge) the largest single-institutional VLDRT experience. Impor-
tantly, this series incorporates expert pathology review, use of ISRT,
and a large proportion of patients with PET staging, making it highly




The study received approval from the Memorial Sloan Kettering
Institutional Review Board (#16-1512) and was conducted in
accordance with the Declaration of Helsinki. After Institutional Review
Board approval, we retrospectively analyzed adults treated with
VLDRT. Patients who received 4 Gy before transplant total body
irradiation were excluded. All had biopsy-confirmed mature B-cell
lymphomas reviewed by an expert hematopathologist, including FL
(grade 1-3A), MZL, or low-grade disease indistinguishable from FL
and MZL and not otherwise specified. Lesions that had been
completely excised were excluded.
VLDRT characteristics
The VLDRT treatment approach was determined by lesion anatomy
and size. Our practice generally incorporates PET-based simulation.
Patients who received VLDRT were treated with ISRT principles
defined by International Lymphoma Radiation Oncology Group
(ILROG) guidelines for nodal,27 extranodal,28 and cutaneous29
NHL. Patients received nonstandardized surveillance after VLDRT;
reassessment was typically 8 to 12 weeks after VLDRT.
Study end points and statistics
The primary end point was incidence of LP, defined as radiographic or
clinical relapse within the VLDRT treatment field. The primary
statistical method was cumulative incidence of LP analyzed per lesion
with death as a competing risk. We elected to consider death as the
only competing risk to maximize analyzable events in a real-world
setting and for comparability to the primary FoRT outcomes, which did
not censor subsequent systemic therapy.24,25 Given the possibility
that early deaths or initiation of systemic therapy before LP might
influence cumulative incidence of local failures, we compared this
analysis with a Kaplan-Meier analysis of LP, censoring for death or
receipt of systemic therapy after VLDRT. This additional statistical
approach also aimed to assess the robustness of our findings using
competing risk analysis and to allow comparability to the secondary
analysis from the long-term FoRT update, which did censor sites at the
time they received additional therapy before local failure.25
Outcomes were analyzed for the full cohort and stratified into 2
subgroups by VLDRT treatment intent. Potentially curative lesions
were defined as localized (stage I-II) sites in patients without previous
lymphoma-directed treatment, treated comprehensively with VLDRT.
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Other lesions, including advanced-stage or status after previous
treatments (even if localized at VLDRT) were considered non-curable
intent. Univariable and multivariable competing risk regressions were
used to identify potential associations with LP. These results were
compared with univariable and multivariable Cox regression analysis
of LP censoring for death and systemic therapy. Follow-up was
estimated by using a reverse Kaplan-Meier method.
The secondary end point was best response after VLDRT (clinical or
radiographic using Lugano criteria) analyzed per lesion.30 ORR
includes CR or partial response (PR). A multivariable logistic
regression model was constructed using lesion size, histology, extent
of previous systemic therapy, lesion site, lesion type, standardized
uptake value (SUV), and treatment intent to identify associations with
CR between 1.5 and 6 months. After 6 months, completely
responding lesions were deemed to be successfully treated, and
patients would not be likely to have subsequent therapy recom-
mended for them. Given the variability in time to response assess-
ments, associations between best response and LP were analyzed by
using a landmark analysis for 6 months after VLDRT.
Additional end points included distant progression (DP) outside the
VLDRT field and composite overall progression (OP) comprising LP,
DP, any additional RT, or systemic therapy. Pathological confirmation
after VLDRT relapse was not required, except for establishing
transformation to diffuse large B-cell lymphoma (DLBCL). OS was
estimated by using the Kaplan-Meier method. Cumulative incidence of
DP, OP, receipt of additional treatment, and transformation to DLBCL
were analyzed per patient controlling for competing risk of death.
Given the possibility that previous exposure to systemic therapy could
theoretically influence the efficacy of VLDRT, we also performed a
subset analysis of the patients who received no previous systemic
therapy. For this subset, we evaluated LP and OP after VLDRT
response as well as cumulative incidence of LP andOP. Comparisons
of cumulative incidence and Kaplan-Meier curves between lesions
and patients treated with curative or palliative intent were assessed by
using Gray’s test and log-rank tests, respectively. All time-to-event
analyses were measured from the start of VLDRT. Statistical tests
were two-sided, and P values of , .05 were considered significant.
Statistics were performed using R version 4.0.1.31
Results
Patient characteristics
A total of 299 sites from 250 adult patients treated with VLDRT
between 2005 and 2018 were included. Patient characteristics are
summarized in Table 1. Heterogeneity among patients was reflective
of a mix of limited and advanced stages, and 10% of patients received
VLDRT for retrograde transformed DLBCL. Bone marrow biopsy was
available for 147 patients (59%) of whom 42 (29%) were positive.
Characteristics of treated sites
Table 2 provides descriptive statistics per lesion overall (n5 299) and
stratified by treatment intent as either non-curable (n5 247; 83%) or
potentially curable (n 5 52; 17%). Nearly one third (29%) received
VLDRT as first-line treatment. Histologic distribution was 66% FL,
27% MZL, and 7% low-grade not otherwise specified. VLDRT was
used most often for limited-stage disease, either stage I and localized
(40%) or stage II (24%). Most sites (83%) were PET staged, of which
34 lesions (14%) were either non-avid or with SUV similar to
background. Of the remaining 217 lesions, median pre-VLDRT
maximum SUV was 7.3 (range, 0.7-27.0).
Sites treated with VLDRT had significant anatomic diversity. Median
pre-VLDRT maximum diameter was 2.6 cm (range, 0.1-12.5 cm), and
9% were$6 cm. Treated sites were extranodal (55%), nodal (41%),
or both (5%). Common extranodal sites included cutaneous (17%)
and orbit (9.7%), whereas common nodal sites included head and
neck (14%) and inguinofemoral (9.7%). A complete breakdown of
anatomic sites is provided in supplemental Table 1.
We identified 50 potentially curable patients with treatment to 52
sites. Lesions were treatment naïve (8% were observed before
VLDRT) and were comprehensively encompassed within VLDRT
fields. Of 52 lesions, 96% were PET/CT staged as stage I (50%),
stage II (12%), or cutaneous with localized disease (38%) (Table 2).
Like lesions in the full cohort, the majority of curable lesions were
extranodal, with leading sites being cutaneous (n5 20; 38%), orbit (n
Table 1. Patient characteristics
Characteristic No. (% [frequency])




Age at first VLDRT, y







Localized (cutaneous) 29 (12)
Multifocal (cutaneous) 2 (0.8)
Unknown 1




Previous diagnosis of DLBCL or aggressive lymphoma 25 (10)
Exposure to systemic therapy before VLDRT





Previous rituximab 95 (38)
Previous chemotherapy or chemoimmunotherapy 85 (34)









 http://ashpublications.org/bloodadvances/article-pdf/5/20/4185/1830033/advancesadv2021004939.pdf by guest on 23 D
ecem
ber 2021
5 8; 15%), and parotid (n5 6; 12%). Other extranodal sites included
breast, duodenum, esophagus, and vulva. Compared with non-
curable lesions, potentially curable sites had a greater nominal
composition of MZL (44% vs 23%) and tended to be smaller (median
maximum diameter of 2.1 cm vs 2.6 cm) and less avid (median
maximum SUV of 5.0 vs 7.8).
Treatment history before VLDRT
Before VLDRT, 54% of patients had received at least 1 cycle of
systemic therapy, including rituximab monotherapy (n 5 95; 38%) or
chemotherapy or chemoimmunotherapy (n5 85; 34%) (Table 1).We
considered oral steroids (or topical or injectable preparations for
cutaneous lesions) as a line of systemic therapy before VLDRT. In
total, 13 sites were treated with some formulation of steroids before
VLDRT. An additional 7 sites received steroids in addition to rituximab.
Four percent of lesions were previously excised; all patients had
residual or recurrent disease. Overall, 22% of lesions were observed
before VLDRT, either after initial diagnosis or after relapse.
VLDRT response
The optimal interval for assessing response after VLDRT has not been
established. Table 3 shows the best clinical and radiographic
responses within the interval of 1.5 to 6 months after VLDRT. There
were 227 evaluable sites with available imaging that met criteria
(76%), and best overall response was recorded if there were multiple
assessments.
Most lesions were reassessed by PET/CT (n 5 155; 68%), CT (n 5
17; 7%), or clinically (n 5 44; 19%), largely for cutaneous sites.
Composite ORR was 90% (n 5 227; CR, 68%; PR, 22%). Overall,
relatively few lesions (5%) progressed through VLDRT, of which the
majority (57%) had concurrent out-of-field progressive disease (PD).
No significant differences in best response were observed when
stratifying the cohort by histology (P. .9) or treatment intent (P5 .2).
Response distribution was similar using intervals of either 1.5 to 3
months or 1.5 to 12 months. Multivariable logistic regression for
associations with achievement of CR identified size as significant
(supplemental Table 2). Compared with lesions ,6 cm, lesions $6









Previously observed site 67 (22) 63 (26) 4 (7.7)
Previous excision
to same site
No 288 (96) 236 (95) 52 (100)
Yes 11 (4) 11 (5) 0 (0)
VLDRT given to newly diagnosed
patient
88 (29) 36 (15) 52 (100)
Histology at VLDRT
FL 197 (66) 177 (72) 20 (38)
MZL 80 (27) 57 (23) 23 (44)
Low-grade indolent NOS 22 (7.4) 13 (5.3) 9 (17)
Stage at time of VLDRT
I 99 (33) 73 (30) 26 (50)
II 72 (24) 66 (27) 6 (12)
III 43 (14) 43 (17) 0 (0)
IV 63 (21) 63 (26) 0 (0)
Localized (cutaneous) 20 (6.7) 0 (0) 20 (38)
Multifocal (cutaneous) 2 (0.7) 2 (0.8) 0 (0)
Modality of staging
at time of VLDRT
PET/CT 249 (83) 199 (81) 50 (96)
CT 32 (11) 32 (13) 0 (0)
MRI 6 (2.0) 4 (1.6) 2 (3.8)
Mammogram 2 (0.7) 2 (0.8) 0 (0)
Clinical 10 (3.3) 10 (4.0) 0 (0)








Pre-VLDRT lesion size, cm†
0-2 79 (30) 63 (28) 16 (39)
2-4 115 (44) 94 (42) 21 (51)
4-6 47 (18) 45 (20) 2 (4.9)
$6 23 (8.7) 21 (9.4) 2 (4.9)
Unknown 35 24 11
Nodal characteristics
of treated fields
Extranodal 163 (55) 123 (50) 40 (77)
Nodal 122 (41) 111 (45) 11 (21)
Both 14 (4.7) 13 (5.3) 1 (1.9)
Site category
Skin 51 (17) 31 (13) 20 (38)
Head and neck (nodal) 43 (14) 41 (17) 2 (3.8)
Eye and orbit 29 (9.7) 21 (8.5) 8 (15)
Inguinofemoral 29 (9.7) 27 (11) 2 (3.8)









Data are presented as n (% [frequency]) unless otherwise stated.
MRI, magnetic resonance imaging; NOS, not otherwise specified.
*Continuous variable.
†Categorical variable.










Pre-VLDRT PET highest SUV†
0-5 53 (21) 39 (19) 14 (29)
5-7.5 58 (23) 50 (25) 8 (16)
7.5-10 41 (16) 37 (18) 4 (8.2)
10-15 56 (22) 53 (26) 3 (6.1)
$15 9 (3.6) 8 (4.0) 1 (2.0)
Unspecified but less than liver
background
34 (14) 15 (7.4) 19 (39)
Unknown 48 45 3
Data are presented as n (% [frequency]) unless otherwise stated.
MRI, magnetic resonance imaging; NOS, not otherwise specified.
*Continuous variable.
†Categorical variable.
‡A total of 82 lesions had unspecified or unknown SUV.
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cm were less likely to achieve CR (odds ratio, 0.17; 95% confidence
interval [CI], 0.04-0.65; P 5 .013).
Local control after VLDRT
Median follow-up was 2.4 years (95%CI, 2.2-3.1 years) for the overall
cohort, 2.5 years (95% CI, 2.3-3.5 years) for the non-curable
subgroup, and 1.7 years (95% CI, 1.2-3.5 years) for the potentially
curable subgroup. VLDRT was well-tolerated without any serious
toxicities. In total, 81 (27%) of 299 sites developed LP. The 1-year
cumulative incidence of LP was 22% (95% CI, 18%-27%), 2-year
was 25% (95% CI, 20%-31%), and 5-year was 33% (95% CI, 26%-
39%) (Figure 1A). Patients in the potentially curable subgroup had
considerably lower 2-year LP of 9% (95% CI, 3%-19%) compared
with 29% (95% CI, 23%-34%) for patients in the non-curable























CR 154 (68) 117 (65) 37 (80) 95 (66) 47 (72) 12 (67) 56 (62) 98 (72) 35 (85) 119 (64)
PR 49 (22) 42 (23) 7 (15) 34 (24) 11 (17) 4 (22) 20 (22) 29 (21) 5 (12) 44 (24)
SD 13 (5.7) 11 (6.1) 2 (4.3) 8 (5.6) 4 (6.2) 1 (5.6) 7 (7.8) 6 (4.4) 1 (2.4) 12 (6.5)
PD 11 (4.8) 11 (6.1) 0 (0) 7 (4.9) 3 (4.6) 1 (5.6) 7 (7.8) 4 (2.9) 0 (0) 11 (5.9)
Data are n (%).
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Analysis method CIF 1-KM
VLDRT intent Non-curable Potentially curable
Figure 1. Cumulative incidence of local progression. Cumulative incidence (CIF) of LP assuming death as competing risk after treatment with VLDRT for the (A) overall
cohort and (B) stratified by treatment intent with Gray’s test P value. Comparison of analytic methods for LP: CIF vs Kaplan-Meier (KM) curve censoring for death and start of
systemic therapy (1-KM) after VLDRT for (C) the entire cohort and (D) stratified by intent of VLDRT.
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subgroup (Figure 1B). When comparing analytic methods, we found
that the probabilities of LP are visually similar irrespective of the
approach: cumulative incidence with death as a competing risk vs
Kaplan-Meier analysis censoring death and systemic therapy
(Figure 1C-D).
Univariable competing risk regression identified several factors
associated with LP (Table 4). To assess association between best
response and subsequent LP, we performed a landmark analysis at 6
months after VLDRT. With 235 evaluable lesions, we found that not
achieving CR by 6 months after VLDRT increased risk of LP (HR, 2.8;
95%CI, 1.5-5.1; P5 .001). Next, we fit a multivariable competing risk
regression model with stage at VLDRT and all statistically significant
factors from univariable models. By multivariable modeling, larger
lesion size and best response were the only significant factors (Table
5); lesions $6 vs ,6 cm had significantly greater LP risk (HR, 4.7;
95% CI, 1.8-12.6; P 5 .002) as did a non-CR response (HR, 2.3;
95%CI, 1.1-5.1; P5 .036). The estimated HR for extranodal vs nodal
lesions was 0.57 (95% CI, 0.3-1.2). After adjusting for other factors,
curable intent was not associated with a lower risk of LP. As a
sensitivity analysis, we compared the univariable and multivariable
competing risk regression analysis to the Cox regression analysis,
which censored death and subsequent systemic therapy. The
statistically significant factors in both univariable and multivariable
models were largely the same, irrespective of approach (supplemental
Tables 3 and 4). These findings suggest little difference between the
2 analytical methods.
Risk of DP and OP
The cumulative incidence of DP increased most rapidly in the first year
after VLDRT (34% [95% CI, 28%-40%] at 1 year and 46% [95% CI,
39%-53%] at 2 years) (Figure 2A). We observed significantly lower
cumulative incidence of DP for potentially curable patients (P, .001;
Figure 2B) with a 1-year probability of 11% (95% CI, 4%-21%) vs
39% (95% CI, 32%-46%) for patients in the non-curable subgroup.
Table 4. Univariable competing risk regression models for LP
Characteristic No. HR 95% CI P
Age at VLDRT (y) 299 1.01 0.99-1.02 .5
Sex 299
Male — —
Female 0.89 0.57-1.37 .6
Histology at VLDRT 299
FL — —
MZL 0.65 0.39-1.11 .12
Low-grade indolent 0.80 0.32-1.97 .6
Best overall response* 235
CR — —
PR, SD, or PD 2.75 1.48-5.10 .001
Maximum SUV before VLDRT 251
0-5 — —
5-7.5 0.82 0.36-1.84 .6
7.5-10 0.68 0.27-1.73 .4
10-15 1.59 0.78-3.24 .2
$15 1.30 0.36-4.74 .7
Unspecified but less than liver background 0.73 0.28-1.88 .5
Stage at VLDRT 299
Early — —
Advanced 1.20 0.77-1.87 .4
Nodal status 299
Nodal — —
Extranodal 0.59 0.38-0.94 .024
Both 1.36 0.57-3.26 .5
Site category 299
Cutaneous — —
Non-cutaneous 1.29 0.69-2.40 .4
Pre-VLDRT lesion size (cm) 264
0-6 — —
$6 5.53 3.23-9.48 ,.001
Intent of VLDRT 299
Non-curable — —
Potentially curable 0.30 0.12-0.73 .008
Previous No. of lines of systemic therapy 299
0 — —
1 1.95 1.06-3.57 .031
2-4 2.23 1.29-3.84 .004
. 4 3.73 1.47-9.47 .006
Previous rituximab 299 1.71 1.10-2.65 .017
*Given the variability in time of best response assessment, this factor was assessed using
a landmark analysis with landmark time at 6 months after VLDRT.
Table 5. Multivariable competing risk regression model for LP
Characteristic HR 95% CI P
Nodal status
Nodal — —
Extranodal 0.57 0.28-1.16 .12
Both 0.72 0.17-3.30 .7
Pre-VLDRT lesion size (cm)
0-6 — —
$6 4.69 1.75-12.62 .002
Intent of VLDRT
Non-curable — —
Potentially curable 0.73 0.17-3.11 .7
Previous No. of lines of systemic therapy
0 — —
1 1.76 0.54-5.77 .3
2-4 1.71 0.53-5.51 .4
. 4 1.15 0.11-12.04 ..9
Previous rituximab 1.04 0.39-2.76 ..9
Stage at VLDRT
Limited — —
Advanced 0.78 0.35-1.75 .6
Best overall response
CR
PR, SD, or PD 2.32 1.05-5.09 .036
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We next considered composite OP and found that 150 patients
(60%) had an event and 6 died with no PD. Median OP-free survival
was 1.0 years (95% CI, 0.8-1.7 years); cumulative OP incidence at 1
year after VLDRT was 49% (95% CI, 42%-55%); at 2 years, it was
60% (95% CI, 53%-66%) (Figure 2C). Just over half the patients
(52%) hadDP as their first OP event, followed by 37%with LP. Again,
patients in the potentially curable group had significantly lower OP vs
those in the non-curative group (P , .001; Figure 2D) with a 1-year
rate of 19% (95% CI, 9%-31%) and a 2-year rate of 27% (95% CI,
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Figure 2. Additional post-VLDRT outcomes. Cumulative incidence of DP after VLDRT for (A) the overall cohort and (B) stratified by treatment intent and of OP after VLDRT
for (C) the overall cohort and (D) stratified by treatment intent with Gray’s test P value. Kaplan-Meier estimates of OS after VLDRT for (E) the overall cohort and (F) stratified by
treatment intent with log-rank test P value. Shading is 95% CI.
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94%) and the 5-year estimate was 78% (95% CI, 70%-86%) (Figure
2E). OS distributions for patients with potentially curable vs non-
curable disease were not significantly different (P 5 .3; Figure 2F),
possibly owing to fewer definitively treated patients with sufficient
follow-up.
Impact of previous systemic therapy on
VLDRT efficacy
Given the heterogeneity among patients in exposure to systemic
therapies before VLDRT and to better isolate the efficacy of VLDRT
alone, we performed a subset analysis of the 114 patients (46%) who
received no previous systemic therapy. This subset included 128
lesions (43%) with a greater share of potentially curable sites
compared with the full cohort (41% vs 17%). Overall, the subset with
no previous systemic therapy (ORR, 94% [77%CR]) seemed to have
a response pattern similar to that for the full cohort (ORR, 90%).
Acknowledging that the subset of patients with no previous systemic
therapy had relatively few LP events (n 5 21), the cumulative
incidence curves seemed to show improvement compared with those
for the full cohort (supplemental Figure 1). In addition, cumulative
incidence of OP for the subset of patients with no previous systemic
therapy was similar to that for the full cohort (supplemental Figure 2).
Additional treatments after VLDRT
Overall, 97 patients (39%) had additional RT and/or subsequent
systemic therapy after VLDRT. Patients with potentially curable lesions
were significantly less likely to receive additional therapy (P, .001). In
total, 34 lesions (11%) were treated with systemic therapy after
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Figure 3. Additional same site RT. Cumulative incidence of (A) receipt of additional RT and (B) subsequent LP after additional RT to same site after VLDRT. Shading is 95% CI.
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Figure 4. Schematic framework for adaptive treatment of patients with iNHL using VLDRT and early PET guidance. MSKCC, Memorial Sloan Kettering Cancer Center.
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(3%) treated with systemic therapy after VLDRT was received for DP
subsequently developed LP.
Additional RT was administered to 45 lesions (15%) treated with
VLDRT for suboptimal response without intercurrent LP in the 6
months after VLDRT (n5 12; 4%), salvage therapy after LP (n5 30;
10%), or more delayed retreatment for marginal recurrence with
overlap of the field previously treated with VLDRT (n 5 3; 1%).
Additional doses ranged from 4 to 50 Gy with the most common
regimens being 4 Gy (n 5 13; 29%), 24 Gy (n 5 11; 24%), and 30
Gy (n 5 11; 24%). The probability of receiving additional RT to the
same site 2 years after VLDRT was 14.6% (95% CI, 10.6%-19.2%;
Figure 3A). Subsequent response after additional RT was 68% CR (n
5 30), 18% PR (n5 8), and 14% nonresponse (n5 6) with 1 lesion
lost to follow-up. There were 8 lesions that progressed locally after
subsequent RT; all had previously documented LP after VLDRT. The
2-year probability of subsequent LP was 15.0% (95% CI, 5.9%-
28.0%; Figure 3B).
There was a trend toward potentially curable lesions having a lower
probability of receiving additional RT to a site previously treated with
VLDRT (P5 .06). For curable lesions that had suboptimal response or
LP after VLDRT, re-treatment with additional RT was effective; 3
lesions (6%) received additional RT, and all resolved completely
without documented LP.
At our institution, we pioneered an adaptive RT strategy that allowed
us to offer VLDRT more broadly to patients who agreed to close
observation (Figure 4). To follow our program, patients with iNHL
started with VLDRT followed by short-interval reassessment (typically
2-3 months) with consideration of additional VLDRT or possibly
escalation to full-dose RT (ie, 20-24 Gy) contingent on the response
to VLDRT. For this analysis, we defined the program as receipt of
additional RT to the VLDRT field within 6 months without intercurrent
LP.
In total, 12 lesions (4%) received additional in-field RT per the
program, of which 3 (25%) received additional 4 Gy and the
remainder received 20 to 30 Gy. Patients who received additional
VLDRT had treatment to the vulva, bilateral orbits/periorbita, bilateral
neck, and Waldeyer’s ring. Although the median SUV for lesions that
required additional RT was nominally higher than that for the overall
cohort (10.1 vs 7.3), we lacked the power to better identify predictors
of a requirement for subsequent RT. After the program, there were 2
LPs and 7 DPs.
Impact of best response on early clinical events
Our landmark analyses at 6 months did not capture the full impact of
early progression because LP often occurs in the first year (Figure 1).
Thus, we performed an exploratory analysis of association between
best response by 6 months and risk of either LP or the composite end
point of LP, additional in-field/out-of-field RT, systemic therapy, or
death at 6 months. Patients who did not achieve CR had higher
proportions of both events, which suggests that early responses have
clinical importance (P, .001; Table 6). Overall, 68 lesions (23%) had
PR to VLDRT, 27 (40%) subsequently developed LP, 4 (6%) received
systemic therapy without LP, and the remaining 37 (54%) had no
recorded LP.
Risk of histologic transformation
Before treatment with VLDRT, 25 patients (10%) had a history of
DLBCL and received VLDRT for relapse of an indolent component (ie,
retrograde transformation). Of these 25, 10 (40%) developed
recurrent DLBCL after VLDRT. Of the 225 patients without previously
diagnosed DLBCL, 9 (4%) had DLBCL transformation, and none
were potentially curable. All cases of transformed DLBCL were
diagnosed distant to the VLDRT fields. The 2-year cumulative
incidence of transformation was 1.7% (95% CI, 0.5%-4.5%) and
the 5-year incidence was 8.5% (95% CI, 3.6%-15.9%) (Figure 5).












LP at 6 mo after VLDRT ,.001
LP 36 (13) 5 (2.9) 7 (11) 24 (62)
No LP 240 (87) 167 (97) 58 (89) 15 (38)
Event at 6 mo after VLDRT ,.001
Composite 65 (24) 16 (9.3) 19 (29) 30 (77)
None 211 (76) 156 (91) 46 (71) 9 (23)
Data are presented as n (% [frequency]). Composite event includes LP, additional local RT, systemic therapy, or death following VLDRT.
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Figure 5. Cumulative incidence of DLBCL transformation or diagnosis after
VLDRT.








VLDRT is a versatile, effective strategy for treating iNHL. With a
median follow-up of more than 2 years, we demonstrated that modern
VLDRT approaches using PET staging and ISRT results in excellent
ORR and nearly 70% CR. Importantly, most lesions remain controlled
with low probability of progression at 2 years after VLDRT. We also
report very low probability of transformation and none within the
VLDRT field. Although additional follow-up is required, the LP
cumulative incidence curve starts to plateau, which suggests the
possibility of durable response.Overall, medianOP-free survival was 1
year, suggesting that VLDRT can offer meaningful remission and
stability.
Our composite ORR is concordant with other published VLDRT
series (Table 7). Our reported CR rate is higher than the historical
median (59%), which may be the result of rigorous pathology review
or inclusion of cutaneous lymphomas. Furthermore, we had greater
use of PET for response assessment compared with older series that
relied on CT or clinical assessments. For FL, a significant proportion of
PR by CT will be metabolically CR.32 Similar ORR and LP outcomes
for VLDRT across our heterogeneous population highlight its versa-
tility. We have used a large cohort to confirm findings from numerous
centers that VLDRT works well in diverse clinical contexts: FL or MZL
histology, early or advanced stage, nodal or extranodal lesions, or
heavily pretreated or treatment naïve patients.14,15,17-19,21,22,24,33,34
We performed a subset analysis of patients who received no previous
systemic therapy, and the similarity of the cumulative incidence curves
of LP and OP compared with those of the full cohort suggest that the
direct efficacy of VLDRT is robust.
To guide patient selection for treatment with VLDRT, researchers have
attempted to identify predictive characteristics for durable response.
In our series, only the pretreatment size of the lesion was associated
with greater risk of suboptimal response and LP. The observation that
larger lesions may be suboptimally treated with VLDRT has been
suggested, but a specific bulky disease threshold remains uncertain.
In our work, lesions$6 cm have poorer relative outcomes. Girinsky et
al15 and K€onig et al35 both reported that diameter .5 cm had
significantly lower ORR and greater LP. Haas et al19 noted similar
ORR but significantly lower CR rates for bulky (.5 cm) vs smaller
sites (P 5 .006). Others report a significant CR difference between
lesions#4 cm and those.4 cm (90% vs 56%; P5 .04), although it
was unclear whether this was related to proportional differences of
head and neck (vs pelvic) sites.20
The current role of VLDRT has been shaped by the phase 3 FoRT
study, which found that 4 Gy had inferior time to LP compared with 24
Gy.24,25 Critics of VLDRT argue that inferior local control makes it
unsuitable outside of palliation. We and others support a more
Table 7. Selected prospective and retrospective series investigating VLDRT for iNHL
















This study 2021 Retrospective ISRT 66% FL, 27% MZL, and 7%
low-grade NOS
250 299 26 90 68 22 2-y cumulative incidence of
LP for overall, 25%; non-
curable, 29%; potentially
curable, 9%
24,25 2014, 2021 Randomized, phase 3,
noninferiority of 4 Gy vs 24
Gy (FoRT)
IFRT 56% FL, 7% MZL, 6% other
(ie, CLL, DLBCL, HL),
12% no diagnosis
possible, 21% with no
central review
281 315 74 81 49 32 LPFS at 5 y: 89.9% after 24
Gy and 74.4% after 4 Gy
(P , .001)
21 2008 Phase 2 IFRT 62% indolent (mostly FL) and
36% aggressive lymphoma
36 47 5 86* 48* 38* Median time to LP for the
entire group, 15 mo
19 2005 Phase 2 IFRT SLL and CLL (n5 23), MZL (n
5 18), MCL (n 5 17),
DLBCL (n 5 13)
71 177 9 93* 56 37 Median time to LP for iNHL,
23 mo
18 2003 Phase 2 (HORA-1) IFRT FL 90%, MZL 8%,
lymphoplasmacytoid
lymphoma 2%
109 304 7 92 61 31 Median time to LP, 25 mo
17 2002 Phase 2 IFRT 68% iNHL, 32% CLL 22 31 8 87* 74* 13* Median time to LP for full
group, 22 mo
35 2018 Retrospective 57% FL, 43% MZL 47 50 21 90 LPFS at 2 y for all patients,
91.1%; curative, 96.7%;
palliative, 83.8%
34 2013 Retrospective IFRT 66% FL, 9% CLL or SLL,
10% MZL, 6% MCL,
8% other
127 187 23 82 57 25 Median time to first
recurrence, 13.6 mo
22 2011 Retrospective 56% indolent, 28% CLL,
13% aggressive, 2% of
sites were other
54 85 16 88* 71 17 LPFS at 2 years, 50%
20 2008 Retrospective IFRT FL 85%, MZL 6%, MCL 6%,
CLL 3%
33 43 14 95 84 12 Median time to LP, 9 mo
15 2001 Retrospective IFRT 100% low-grade lymphomas 48 135 54 81 57 24 LPFS at 2 y, 56%
LPFS, local progression-f ree survival.
*Outcomes of only the indolent subgroup of studied patients.
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positive interpretation of the data; for lesions treated with VLDRT,
median time to LP was not reached, which suggests that most lesions
will be controlled with 4 Gy. Furthermore, given that there were no
differences in OS between the arms, patients treated with VLDRT can
successfully receive salvage therapy or face death as a result of
unrelated causes in similar proportions.
Furthermore, focusing purely on local control likely fails to capture the
bigger picture of the iNHL clinical trajectory. Patterns of treatment
failure for this cohort demonstrate that after VLDRT, patients are more
likely to experience out-of-field DP. The 2-year cumulative incidence
estimate of DP was 46% vs 25% for LP. This observation aligns with
well-understood iNHL behavior and previous trends from series using
extended fields or IFRT. For example, in the Dutch experience, median
time to overall progression was 14 months and 25 months for LP.18
Although it may be attractive to consider higher doses of RT to
improve the durability of local control, it is unlikely that dose escalation
will meaningfully change the broader disease course. A recently
published ILROG multicenter analysis of curative dose RT (.24 Gy)
for newly diagnosed, localized, PET-staged FL found that although
in-field recurrence was extremely low (1.8%), 5-year freedom from
progression was 69% overall (74% for stage I and 49% for stage II).7
Use of VLDRTwith curative intent remains particularly controversial.
The FoRT study originally focused on palliatively treated patients
but expanded to include patients with curable lesions. Roughly
40% of lesions were curable, and ORR was significantly better for
24 Gy (82% vs 95%; P 5 .005) as was the durability of local
control. In our series, 52 lesions were potentially curable, and we
did not detect any signals suggestive of inferior outcomes; we
observed significantly lower incidence of DP and OP without
DLBCL transformation. There are a number of possible reasons
why the outcomes for sites in the potentially curable subgroup are
improved compared with the palliatively treated sites. First, early-
stage disease not exposed to chemoimmunotherapy might have
more indolent biology. Second, the potentially curable sites were
slightly smaller and had a greater proportion of extranodal lesions
and MZL histology, both of which have better overall outcomes. Of
note, the potentially curable subgroup included a moderate
proportion of cutaneous disease which is known to have excellent
outcomes with distinct clinical course. Given these caveats, for
now, we would caution against using VLDRT as a curative strategy
for certain populations, including those with bulky tumors (.6 cm)
or patients unable to return for close follow-up.
VLDRT is attractive to patients because of its logistical convenience
and minimal toxicity risk (particularly when compared with systemic
therapy). In the FoRT trial, patients who received 4 Gy had a ,1%
chance of severe toxicities. We feel comfortable treating appropriately
counseled patients who have curable disease with VLDRT, given our
adaptive program (Figure 4). Our experience suggests that relatively
few patients will require subsequent RT, but one important caveat is
that patients were treated off-protocol; this series included a highly
selected, potentially lower-risk group, and recommendations for
subsequent RT were not standardized. With close follow-up and
indolent disease course, patients receiving first-line VLDRT are
unlikely to face a significant risk of rapid progression or lose a
window of curability. VLDRT with curative intent has already been
proposed for orbital and salivary gland MZL in which higher doses are
associated with increased toxicity.36-38 Patients must be appropriately
counseled regarding a likely greater LP risk, and they should also
understand that most lesions can be effectively re-treated.We confirm
the observations of other researchers,19,39 that re-irradiation is safe
and maintains similar efficacy after VLDRT.
PET-adapted RT already plays an important role across lymphoma
indications,40,41 but its predictive power to determine control after
VLDRT should be prospectively validated. Our data suggest that
higher doses could be considered for bulk, but this remains a crude
and imperfect guide, and we have relatively little ability to predict
which patients will have a durable response. Attempts to identify
radiogenomic predictors to better discriminate optimal candidates are
under way at our institution and at others. Moving forward, it may be
sensible to design a randomized trial that compares patients who
receive 4 Gy or adaptive 24 Gy before LP with those who receive 24
Gy a priori with consideration of a broader constellation of clinical,
radiogenomic, and quality-of-life outcomes.
We see numerous opportunities to expand VLDRT indications.
Because VLDRT may induce local and systemic immunomodulation,
there are natural opportunities to consider combinations with diverse
systemic therapies.33 The TROG99.03 study found that patients with
early-stage FL who received 30 Gy IFRT with rituximab, cyclophos-
phamide, vincristine, and prednisone (R-CVP) chemoimmunotherapy
had significantly improved progression-free survival when compared
with IFRT alone.42 Patients with greater risk of treatment failure after
VLDRT (eg, those with bulky lesions) could be considered for adjuvant
systemic therapy. Building on these concepts, the GAZAI study aims
to use response-adapted ISRT initially with 4 Gy plus obinutuzumab
for early-stage grade 1 to 2 FL.43 Excellent tolerability, even when
irradiating large fields, means that VLDRT can be considered for
patients with significant disease burden as a bridge to next-line
systemic therapies, even for aggressive lymphomas.44
Strengths of this analysis include a large number of sites, use of PET,
consideration of numerous end points using competing risk method-
ology (given the epidemiology of the disease), and rigorous pathology
review. Of note, FoRT did include a moderate number of patients
without central pathologic confirmation or non-iNHL histologies.24We
also performed a subset analysis to isolate the efficacy of VLDRT
directly without potential confounding from exposure to previous
systemic therapy.
Limitations include the typical biases of retrospective analysis, a
nonstandardized follow-up schedule, imaging approach, and lack of
objective criteria for recommending additional RT. This series includes
several indolent subtypes, including cutaneous, which have different
natural histories but represent real-life institutional use of VLDRT. Our
follow-up was longer than that in most previous VLDRT series, but it
remains relatively short (given the epidemiology), particularly for the
patients with potentially curable disease. In addition, the only
competing event considered in the LP analysis was death, which
may not capture how receipt of previous VLDRT systemic therapy
confounds the probability of LP. However, a comparison analysis
shows that the cumulative incidence curves overlap nearly completely
with inverse Kaplan-Meier curves censoring for death and start of
systemic therapy.
In conclusion, we find that VLDRT that uses modern approaches is an
effective and versatile strategy for iNHL. Future efforts will focus on
refining our understanding of how to optimally incorporate this
modality into evolving lymphoma treatment paradigms that are
increasingly reliant on novel systemic agents.
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